Key Developments: Harris and Harris Group Inc (TINY.W)
3.26USD
23 May 2013
$-0.08 (-2.40%)
$3.34
$3.26
$3.26
$3.26
100
250
$4.24
$3.06
Latest Key Developments (Source: Significant Developments)
Harris and Harris Group Inc Names Patricia N. Egan As Chief Financial Officer
Harris and Harris Group Inc announced that it has appointed Patricia N. Egan as Chief Financial Officer, effective January 1, 2013. Full Article
Harris and Harris Group Inc Notes Ensemble Therapeutics And Boehringer Ingelheim Collaboration
Harris and Harris Group Inc announced the initiation of a research collaboration with Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called macrocycles, against several high-value pharmaceutical targets specified by Boehringer Ingelheim. Under the terms of the agreement, Ensemble is eligible to receive payments and may receive up to $186 million in success milestones in case of full commercial success of multiple drug products, including an upfront payment and research funding. In addition, Ensemble is eligible to receive royalties on future sales of products that arise from the collaboration. Full Article
Harris & Harris Group Notes OpGen, Inc And Life Technologies Corp Collaboration Agreement
Harris & Harris Group, Inc. announced that OpGen, Inc and Life Technologies Corporation have signed a collaboration agreement to develop systems, technologies and applications intended to improve the management and surveillance of microbial outbreaks in the public health and infectious disease markets. The OpGen-Life Technologies collaboration will focus on developing applications and analysis systems that enable the use of the companies' Whole Genome Mapping and Ion Torrent sequencing technologies for food outbreak and infectious disease analysis. OpGen's Whole Genome Mapping technology provides a rapid, comprehensive structural analysis of microbial genomes that, when combined with sequencing data, more accurately detects important genetic elements associated with toxicity, virulence and drug resistance. Full Article
Harris & Harris Group, Inc.'s Mersana Therapeutics, Inc Entered Into Collaboration With Endo Pharmaceuticals
Harris & Harris Group, Inc. announced that its portfolio company, Mersana Therapeutics, Inc., entered into a collaboration agreement with Endo Pharmaceuticals to develop antibody-drug conjugates (ADCs). Mersana's proprietary conjugation technology is comprised of its Fleximer polymer and a broad array of customizable linker chemistries for attaching diverse, potent payloads and targeted antibodies. Under this agreement, Endo will pay an upfront fee to Mersana for the right to utilize the Fleximer technology to develop ADC candidates against a single cancer target. Under the collaboration, Mersana is responsible for conducting research and creating Fleximer‑ADCs that are conjugates of its cytotoxic payloads, Fleximer, and Endo's antibodies. In addition to providing antibodies, Endo is responsible for product development, manufacturing and commercialization of any Fleximer-ADC products. Mersana and Endo may mutually agree to pursue two additional targets over the next two years. In the event that all three targets are pursued, Mersana is eligible to receive more than $270 million in progress-dependent milestones as well as royalties on worldwide net sales of any resulting Fleximer-ADC products. Full Article
Harris & Harris Group, Inc. Disposes Stake In Innovalight, Inc.
Harris & Harris Group, Inc. announced DuPont and Innovalight, Inc., today announced the acquisition of Innovalight, Inc., a privately held, venture-funded, solar cell technology company headquartered in Sunnyvale, CA. Harris & Harris Group made its initial investment in Innovalight in April 2006. As of March 31, 2011, Harris & Harris Group valued its position at $3,920,428. Harris & Harris Group expects to receive up to approximately $5.4 million in this transaction. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
